Christian Jurinke, Ph.D., Caprotec’s head of product commercialization and distribution, has been appointed president of the new U.S. subsidiary. The business is also partnering with Genovative Solutions to help boost sales of CCMS products and services in North America.

The CCMS technology has been developed to target, capture, and isolate selected proteins, including membrane proteins, out of any complex biological sample, based on their functionality.

The approach uses synthetic Capture Compound molecules to interrogate native proteins, including lipophilic membrane proteins, in virtually any biological sample. Caprotec is commercializing CCMS through preconfigured caproKits™, and through contract services based on already available Capture Compounds. The company also works in collaboration with companies and researchers in areas including drug interaction protein profiling, drug target identification, and evaluating drug mode of action and off-target side effects.

The first two caproKits, SAH caproKit, and cAMP caproKit, were launched in January. CaproKits are currently available for protein kinases, cAMP- and cGMP-binding proteins, methyl transferases, and metalloproteases. New kits are also constantly being developed.

The CCMS process can be described as a homogeneous reverse high-throughput screening, Caprotec explains. In essence, the proteome is treated as a library and screened for individual proteins that interact with the highly selective Capture Compounds. The features of CCMS hinge on the multifunctionality of these synthetic Capture Compound molecules. Not only do Capture Compounds function selectively, e.g., for an enzyme substrate/inhibitor, a co-factor or drug candidate), but they also have a reactivity function, to covalently bind the protein target. A sorting function then pulls the Capture Compound-protein-complex directly out of cell lysates.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

42.9%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

14.3%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.